A
AC Immune SA (ACIU)
NGM – Real vaqt narxi. Valyuta: USD
2.77
-0.06 (-2.12%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
2.77
-0.06 (-2.12%)
Yopilishda: May 12, 2026, 4:00 PM EDT
AC Immune SA, klinik bosqichdagi biofarmatsevtika kompaniyasi, oqsil noto'g'ri katlanishiga bog'liq neyrodegenerativ kasalliklarni oldini olish va davolash uchun dori-darmonlar, shuningdek, terapevtik va diagnostik mahsulotlarni kashf qiladi, ishlab chiqadi va yaratadi. Kompaniyaning SupraAntigen va Morphomer platformalari biologik va kichik molekulalarni yaratish uchun mo'ljallangan bo'lib, ular turli xil neyrodegenerativ kasalliklarda keng tarqalgan noto'g'ri katlangan oqsillar bilan tanlab o'zaro ta'sir qiladi. U Alzheimer kasalligining (AD) rivojlanishini sekinlashtirish uchun ishlatiladigan insonlashtirilgan, konformatsion-spetsifik monoklonal antikor bo'lgan Crenezumabni; va ADni davolash uchun Tau oqsilining N-terminal qismini maqsad qilib olgan va Tauga bog'lanib, uning neyronlar orasidagi tarqalishini sekinlashtirish uchun mo'ljallangan tadqiqotdagi monoklonal anti-Tau antikor Semorinemabni ishlab chiqadi. Kompaniya, shuningdek, Daun sindromi bilan bog'liq ADni davolash uchun ACI-24.060; Parkinson kasalligini davolash uchun ACI-7104.056; va bemorning immunitet tizimini patologik fosforlangan Tauga qarshi antikorlar ishlab chiqarishga undash uchun mo'ljallangan ACI-35.030ni ishlab chiqmoqda. Qo'shimcha ravishda, u AD, shuningdek, AD bo'lmagan Tauopatiyalar uchun Tau diagnostikasi bo'lgan PI-2620ni; va ko'plab tizimli atrofiyani boshqa neyrodegenerativ kasalliklardan differensial tashxislashni qo'llab-quvvatlaydigan alfa-sinuklein PET traceri bo'lgan ACI-12589 va ACI-15916ni o'z ichiga olgan diagnostika dasturlarini ishlab chiqadi. Bundan tashqari, kompaniya ADdagi nomzodlarni baholash uchun Morphomer Tau agregatsiya inhibitörlerini; alfa-sin agregatsiyasining kichik molekulyar inhibitörleriyle raqobatlashish uchun Morphomer alfa-sinni; va NeuroOrphan Tauopatiyalarni tadqiq qilmoqda va ishlab chiqmoqda. Qo'shimcha ravishda, u TDP-43, alfa-sinuklein va NLRP3ni maqsad qilib olgan diagnostik vositalarni o'z ichiga olgan bir qator neyrodegenerativ kasalliklarni maqsad qilib olgan kashfiyot va preklinik bosqichdagi molekulalarni yaratadi. Kompaniya Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; va Eli Lilly and Company bilan litsenzion shartnomalar va hamkorliklarga ega. AC Immune SA 2003 yilda ro'yxatga olingan va shtab-kvartirasi Shveytsariyaning Lozanna shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrea Pfeifer Ph.D. | Co-Founder, CEO & Director |
| Dr. Francesca Capotosti | Senior Vice President of Research |
| Dr. Gary Anthony Waanders Ph.D. | Senior VP of Investor Relations & Corporate Communications |
| Dr. Günther Staffler Ph.D. | Executive Vice President of Development |
| Dr. Julien Rongere Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Dr. Matthias Maurer Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-07 | 6-K | dp244548_6k.htm |
| 2026-03-13 | 6-K | aciu-20260313x6k.htm |
| 2026-02-24 | 6-K | dp241987_6k.htm |
| 2026-02-17 | 6-K | dp241689_6k.htm |
| 2025-12-11 | 6-K | dp238614_6k.htm |
| 2025-11-04 | 6-K | aciu-20251104x6k.htm |
| 2025-09-04 | 6-K | dp233965_6k.htm |
| 2025-08-05 | 6-K | aciu-20250630x6k.htm |
| 2025-06-20 | 6-K | dp230378_6k.htm |
| 2025-06-11 | 6-K | dp230006_6k.htm |
| Senior VP & General Counsel |
| Dr. Oliver Sol M.D. | VP & Head of Clinical Development |
| Mr. Christopher Roberts | CFO & VP of Finance |
| Mr. Mark Danton | Executive Vice President of Information Systems & Artificial Intelligence |
| Mr. Piergiorgio Donati | Chief Operating Officer |